USP10 and chronic myelogenous leukemia, BCR-ABL1 positive: USP10 stabilizes SKP2 and therefore activates the SKP2/Bcr-Abl signaling pathway, potentially leading to increased proliferation of both imatinib-sensitive and imatinib-resistant CML cells [34].